Islet neogenesis associated protein (INGAP) protects pancreatic β cells from IL-1β and IFNγ-induced apoptosis

Eni Nano1, Maria Petropavlovskaia2,3 and Lawrence Rosenberg1

Abstract
The goal of this study was to determine whether recombinant Islet NeoGenesis Associated Protein (rINGAP) and its active core, a pentadecapeptide INGAP104–118 (Ingap-p), protect β cells against cytokine-induced death. INGAP has been shown to induce islet neogenesis in diabetic animals, to stimulate β-cell proliferation and differentiation, and to improve islet survival and function. Importantly, Ingap-p has shown promising results in clinical trials for diabetes (phase I/II). However, the full potential of INGAP and its mechanisms of action remain poorly understood. Using rat insulinoma cells RINm5F and INS-1 treated with interleukin-1β (IL-1β) and interferon-gamma (IFN-γ), we demonstrate here that both rINGAP and Ingap-p inhibit apoptosis, Caspase-3 activation, inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production, and explore the related signaling pathways. As expected, IL-1β induced nuclear factor kappa B (NF-κB), p38, and JNK signaling, whereas interferon-gamma (IFN-γ) activated the JAK2/STAT1 pathway and potentiated the IL-1β effects. Both rINGAP and Ingap-p decreased phosphorylation of IKKα/β, IkBa, and p65, although p65 nuclear translocation was not inhibited. rINGAP, used for further analysis, also inhibited STAT3, p38, and JNK activation. Interestingly, all inhibitory effects of rINGAP were observed for the cytokine cocktail, not IL-1β alone, and were roughly equal to reversing the potentiating effects of IFNγ. Furthermore, rINGAP had no effect on IL-1β/NF-κB-induced gene expression (e.g., Ccl2, Sod2) but downregulated several IFNγ-stimulated (Irf1, Socs1, Socs3) or IFNγ-potentiated (Nos2) genes. This, however, was observed again only for the cytokine cocktail, not IFNγ alone, and rINGAP did not inhibit the IFNγ-induced JAK2/STAT1 activation. Together, these intriguing results suggest that INGAP does not target either IL-1β or IFNγ individually but rather inhibits the signaling crosstalk between the two, the exact mechanism of which remains to be investigated. In summary, our study characterizes the anti-inflammatory effects of INGAP, both protein and peptide, and suggests a new therapeutic utility for INGAP in the treatment of diabetes.

Introduction
Diabetes mellitus is a metabolic disorder characterized by β-cell deficiency and the resulting hyperglycemia. In Type 1 diabetes (T1DM), β cells are destroyed by autoimmunity4, whereas in Type 2 diabetes (T2DM), β-cell failure and death come from progressive insulin resistance, metabolic and oxidative stress, and persistent hyperglycemia2.

Both T1DM and T2DM are characterized by islet inflammation, hyperglycemia, and β-cell apoptosis3,4. Studies in rodents and humans pinpoint pro-inflammatory cytokines and chemokines as key mediators of T1DM pathophysiology and as contributing factors to insulin resistance and β-cell dysfunction in T2DM5,6. Pro-inflammatory cytokines, interleukin-1β (IL-1β), tumor necrosis factor alpha (TNFa), and interferon-gamma (IFN-γ), have been reported to trigger destructive signaling pathways within β cells, leading to elevation of
reactive oxygen species, β-cell dysfunction, and eventually to apoptosis\textsuperscript{5-7}. Inhibition of these signaling pathways is therefore an important therapeutic objective aimed at preventing the progression of diabetes and preserving β-cell mass. Protection of β cells is also essential for regenerative therapies to enable survival and function of transplanted islets or stem cell-generated β cells. In this context, identification of factors with anti-inflammatory, anti-apoptotic and regenerative effects, is of interest.

The goal of this study was to investigate whether INGAP (Islet NeoGenesis Associated Protein), the first known regenerating agent with islet neogenic properties, protects β cells against pro-inflammatory cytokines. INGAP, a 16.8 kDa Reg3δ protein, was discovered in a partially obstructed hamster pancreas as a factor inducing duct-associated islet neogenesis\textsuperscript{8-12}. Several studies have indicated that the islet neogenic activity of INGAP protein is mediated by a pentadecapeptide (Ingap-p, aa104–118)\textsuperscript{11,13-16}, which achieves the same effect, albeit at higher concentrations\textsuperscript{11,16-18}. Importantly, Ingap-p has been proven safe to use in humans and has reached Phase 2 clinical trials. Daily injections of Ingap-p has been used in numerous studies that correlated its duct-to-β-cell neogenic activity\textsuperscript{20,21} and demonstrated its pleiotropic nature including stimulation of insulin secretion, islet survival and function\textsuperscript{22-29}, and angiogenesis\textsuperscript{30}. In addition to increasing functionality and survival of isolated rat islets\textsuperscript{30,31,32}, Ingap-p has been shown to increase viability of islet allografts post-transplantation\textsuperscript{33}.

The full-length INGAP protein expressed in the acinar tissue rendered mice resistant to streptozotocin (STZ)-induced diabetes\textsuperscript{34}. The protective effects of another INGAP transgene expressed in β cells correlated with downregulation of NADPH oxidase NOX1, one of the main mediators of the STZ-induced oxidative damage and DNA fragmentation in islets, thus suggesting that INGAP possesses anti-oxidative properties\textsuperscript{35}. The reported protective effects of INGAP in isolated islets are particularly interesting, suggesting its potential utility for islet transplantation but the mechanisms underlying these effects are unknown. The isolation process causes enzymatic, ischemic, and mechanical stresses that negatively impact islet survival\textsuperscript{36,37}, induce cytokines and chemokines in the islets and activate nuclear factor kappa B (NF-kB), resulting in a strong inflammatory response\textsuperscript{38,39}.

The anti-inflammatory effects of INGAP have not been investigated. We hypothesized that INGAP may offset the cytotoxicity of pro-inflammatory cytokines in β cells and tested our hypothesis using two β-cell lines RINm5F and INS-1 treated with IL-1β and IFNγ, commonly used in the models of cytokine-induced β-cell death\textsuperscript{40}. IL-1β exerts its effects predominantly through the NF-κB pathway\textsuperscript{41}, whereas IFNγ acts mostly through the JAK/STAT1 pathway\textsuperscript{42} but may also activate STAT3\textsuperscript{43,44} and was shown to potentiate the effects of other cytokines\textsuperscript{45-47}. NF-κB activation by IL-1β and IFNγ leads to stimulation of inducible nitric oxide synthase (iNOS) and production of nitric oxide (NO) directly implicated in β-cell apoptosis\textsuperscript{48}. To characterize the anti-cytokine effects of INGAP and to investigate the underlying signaling events we used, as previously\textsuperscript{17,18}, both INGAP-peptide and the full-length recombinant protein (rINGAP).

**Materials and methods**

**Cell culture**

RINm5F cells (ATCC) were cultured at 37°C in a humidified atmosphere of 5% CO\textsubscript{2} in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco\textsuperscript{TM} Life Technologies, Burlington ON, Canada) containing 11 mM glucose, 10% fetal bovine serum (FBS), 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 1 mM sodium pyruvate (Wisent, St-Bruno, QC, Canada) and 1x antibiotics/antimycotics (Gibco\textsuperscript{TM}).

INS-1 cells (AddexBio, San Diego, CA, USA) were cultured in the same medium, supplemented with 50 μM β-mercaptoethanol (Sigma-Aldrich, Oakville, ON, Canada).

Cells passaged every 4–5 days, were plated in six-well (500,000 cells/well), 24-well (200,000 cells/well), or 96-well (40,000 cells/well) TC dishes for 48 h, and serum-starved for 24 h prior to the treatment.

**In vitro model of cytokine-induced β-cell death**

To optimize the conditions for cytokine-induced death, RINm5F and INS-1 cells were treated with either 100 pg/mL IL-1β, 1 ng/mL IFNγ (R&D Systems, Minneapolis, MN, USA), or a cocktail of both and screened for (1) expression of Nos2 by real-time quantitative RT-PCR (qRT-PCR), (2) production of NO in the culture media by Griess assay, and (3) viability by 3-(4,5-dimethylthiazol-2-yi)-2,5-diphenyl tetrazolium bromide (MTT) assay. All experiments were repeated at least three times.

As summarized in Supplementary Fig. 1, Nos2 expression in RINm5F cells (3 h and 6 h) and NO levels in both cell lines (24 h and 48 h) were slightly induced by IL-1β and significantly potentiated by IFNγ, which alone was ineffective (A–C). Vice versa, IL-1β did not reduce viability, which was affected mostly by IFNγ (E). NO levels were significantly increased at 10× and 100× cytokine concentrations, whereas viability varied much less (D, F, G). We concluded that a cocktail of 100 pg/mL IL-1β +1 ng/mL IFNγ was sufficient to induce cytotoxicity in both cell lines.
rINGAP and Ingap-p

Recombinant INGAP, MW 17.6 kDa, was produced in-house, as previously described, and high performance liquid chromatography (HPLC)-purified (Sheldon Biotechnology Centre, McGill University, Montreal, QC, Canada). Ingap-p, MW 1501.6 Da, was synthesized and HPLC-purified (Sheldon Biotechnology Centre or CanPeptide (Pointe-Claire, QC, Canada)). As previously described, 1 nM rINGAP and 1.67 μM Ingap-p were used in most experiments.

Assessment of viability and measurement of NO production

Viability (cellular metabolic activity) was measured by MTT assay. Following cellular treatment in 96-well plates, 20 μL/well of 5 mg/mL MTT (Sigma-Aldrich) was added for 4 h at 37 °C, 5% CO2. Formazan pellets were solubilized with 100 μL/well of 1 N HCl. Absorbance was measured at 570 nm using a microplate spectrophotometer (Bio-Rad Laboratories, Mississauga, ON, Canada). All samples were tested in triplicates and each experiment was repeated 4–5 times. NO production was measured in 50 μL of cell culture media (duplicate samples) using the Griess assay kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. Experiments were repeated three times.

Assessment of apoptosis by Annexin-V/PI FACS analysis

Following treatment, cells were trypsinized, washed with 1× phosphate-buffered saline (PBS) and stained using the FITC Annexin-V Apoptosis Detection Kit with PI (BioLegend, San Diego, CA, USA), following the manufacturer’s instructions. Stained cells and controls (unstained cells, FITC Annexin-V only, and PI only) were then processed by fluorescence-activated cell sorting (FACS) (BD LSR Fortessa, LDI Flow Cytometry Services) and analyzed by FlowJo software. Each experiment was repeated three times.

Real-time quantitative RT-PCR

Cells were lysed in RLT buffer for RNA extraction with RNeasy or RNeasy Plus Kits in QIAcube (Qiagen, Toronto, ON, Canada). One microgram of RNA was reverse-transcribed using the Omniscript kit (Qiagen). Quantitative PCR was performed using custom-made primers (Supplementary Table 1), iQ™ SYBR® Green master mix (Bio-Rad) in CFX96™ Real-Time System (Bio-Rad). Normalized gene expression was calculated using the ΔΔCT method and Gapdh or multiple reference genes (Gapdh, α-tubulin, and β-actin) by the CFX Manager™ software (Bio-Rad). All experiments were repeated at least three to five times.

Immunostaining

Cells (100,000/well) plated in eight-chambered glass slides coated with poly-D-lysine (Sigma-Aldrich) were fixed in 4% paraformaldehyde (10 min, room temperature). Apoptosis was assessed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method using APO-BrDU™ TUNEL Assay Kit (Invitrogen™, Life Technologies). Staining for cleaved caspase-3 with primary antibody (rabbit, 1:100, Cell Signaling Technology, Beverly, MA, USA; 4 °C, overnight) was followed by Alexa488-conjugated secondary antibody (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Slides were mounted with Hardset Vectashield (with DAPI (4′,6-diamidino-2-phenylindole)) (Vector Laboratories, Burlington, ON, Canada) and imaged using Olympus FV10i confocal microscope.

Protein extraction and Western blot analysis

Following the treatments with cytokines, INGAP, and/or pharmacological inhibitors of signaling pathways (Supplementary Table 2), cells were lysed in Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA) or radioimmunoprecipitation (RIPA) buffer (Santa Cruz Biotechnology, Dallas, TX, USA) containing 2.5 mM Na4P2O7, 1 mM Na3VO4, phenylmethylsulfonyl fluoride, and complete protease inhibitor cocktail tablet (Roche, Mississauga, ON, Canada) or Protease Inhibitor Mini Tablets (Fierce/Thermo Scientific, Burlington, ON, Canada) on ice. Equal amounts of protein [20–50 μg, measured with DC Protein assay (Bio-Rad)] were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or stain-free SDS-PAGE (Bio-Rad), transferred onto nitrocellulose membrane (Bio-Rad), and probed with primary antibodies (Supplementary Table 3), secondary anti-mouse or anti-rabbit HRP-conjugated antibodies (Bio-Rad or Cell Signaling Technology), and developed using Clarity Western ECL (Bio-Rad). Chemiluminescence was acquired by ChemiDoc MP (Bio-Rad) and quantified by Image Lab software. Quantification of stain-free blots utilized total protein for normalization. Otherwise, α-tubulin was used as a loading control. Membranes were first incubated with phospho-antibodies, followed by mild stripping (0.2 M glycine, 0.1% SDS, and 0.05% Tween-20, pH 2.2) and re-probing with the corresponding non-phospho-antibodies.

Cytoplasmic and nuclear fractions were isolated using the Nuclear Protein Isolation-Translocation Assay Kit (FIVephoton Biochemicals, San-Diego, CA, USA), following the manufacturer’s instructions, and were analyzed as above. In addition to total lane protein (stain-free gels), α-tubulin and nuclear matrix protein p84 were used as respective loading controls.
**Statistical analysis**

Experiments were repeated three to eight times. The sample size (indicated in Figure legends for each set of data) was guided by the variation of effects and the statistical significance between groups. Results are expressed as means ± SEM of biological replicates. The data were normalized to control values (PBS or cytokines) to determine fold change. To determine data normality for each experiment, residual QQ plots were generated on R (Foundation for Statistical Computing). Data were considered normally distributed when points aligned strongly with the QQ line. Data were analyzed either by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test, two-way ANOVA followed by Bonferroni post hoc test or multiple t test comparisons corrected by Sidak–Bonferroni method. All analyses were performed using Prism 6.0 (GraphPad) software or Microsoft Excel. A P value < 0.05 was considered statistically significant for all comparisons.

**Results**

**rINGAP and Ingap-p protect β cells against cytokine-mediated cell death**

We first pre-treated cells with 1 nM rINGAP or 1.67 μM Ingap-p for 2 h prior to cytokines and measured their viability, apoptosis, and NO production after 24, 48, or 72 h. Most data were obtained in RINm5F cells, using INS-1 cells to confirm some findings. rINGAP significantly improved viability in RINm5F cells (MTT assay, Fig. 1a), and in INS-1 cells (Supplementary Fig. 2A), at all time points, whereas Ingap-p had significant effect only at 24 h (Fig. 1a). Both rINGAP and Ingap-p reduced apoptosis, as assessed by Annexin-V–FITC/PI reactivity after 48 h in RINm5F (Fig. 1b, c) and INS-1 cells (Supplementary Fig. 2B, C), and by the cleaved Caspase-3 immunoblotting (RINm5F cells, 24 h and 48 h, Fig. 1d–g) and immunostaining in both cell lines (Supplementary Fig. 2D, E and 3C, D). This was further corroborated by the decrease in TUNEL-positive cells (47 ± 2.6% (p < 0.001)) and cleaved PARP in RINm5F cells by rINGAP (Supplementary Fig. 3A, B and E, F).

Both rINGAP and Ingap-p downregulated the cytokine-induced expression of iNOS mRNA (Nos2) and protein in RINm5F (Fig. 2a–c) and INS-1 cells (Supplementary Fig. 4A, B) and reduced NO production (Fig. 2d), although rINGAP had a longer-lasting effect (up to 48 h) than Ingap-p. Together, these data show that both rINGAP and Ingap-p partially inhibit cytokine-induced apoptosis in β cells and that this correlates with inhibition of Caspase-3, iNOS expression, and NO production.

We determined next whether the timing of INGAP administration relative to cytokine treatment (±2 h) had an impact on its anti-apoptotic effect. rINGAP reduced cleaved caspase-3 when administered either pre-, co-, or post-cytokine treatment (Fig. 3a, c), whereas Ingap-p was effective in pre- and co- but not post-cytokine treatment (Fig. 3b, d). NO production after 48 h was significantly reduced by rINGAP and Ingap-p in all groups, however, rINGAP was more effective as co- and pre-treatment (Fig. 3e, f). We chose the pre-treatment mode to characterize the signaling mechanism by which rINGAP and Ingap-p elicit anti-apoptotic effects.

**INGAP targets cytokine-induced NF-κB signaling by inhibiting p65 phosphorylation**

In keeping with previous reports, cytokines activated several signaling pathways, most notably NF-κB, JAK-STAT, p38, and JNK (Supplementary Fig. 5). Inhibition of these pathways, particularly NF-κB and JAK-STAT, significantly reduced iNOS, while inhibition of p38 and JNK was less effective (Supplementary Fig. 6A–D). This suggests that NF-κB and JAK/STAT signaling play predominant roles in cytokine-induced cytotoxicity, whereas p38 and JNK are secondary.

NF-κB signaling involves phosphorylation of the IKKα/β and IκBα, leading to IκBα ubiquitination and proteosomal degradation. This allows the NF-κB heterodimer p65 (RelA)/p50 to translocate to the nucleus and modulate transcription. Transcriptional activity, stability, and proteosomal degradation of NF-κB are believed to depend on p65 phosphorylation.

NF-κB activation by cytokines in RINm5F cells induced rapid and transient phosphorylation of IKKβ (Ser32/36) 10 min–1 h, peak at 30 min), and IκBα (Ser32) 10 min–1 h), accompanied by p65 phosphorylation at Ser536 (10 min–6 h, Supplementary Fig. 5A) and p65 nuclear translocation (10 min–3 h, peak at 30 min, Fig. 4a). The peak in P-p65 was at 10 min, preceding that in P-IKK and P-IκBα. This fact, together with limited inhibition by IKKVII (Supplementary Fig. 6E), suggests that p65 phosphorylation was at least partially IKK-independent.

rINGAP and Ingap-p decreased the cytokine-induced phosphorylation of IKK and IκBα (Fig. 4f) but did not inhibit p65 nuclear translocation, which is necessary for exerting the effects of NF-κB signaling on the target genes. In contrary, nuclear p65 was increased in INGAP pre-treated cells (Fig. 4b, c). The cause of this is unclear since rINGAP itself does not induce p65 translocation (data not shown). However, rINGAP significantly decreased p65 phosphorylation at Ser536 between 30 min and 6 h of cytokine treatment (Fig. 4d, e). Same effect was observed for Ingap-p at 6 h (Supplementary Fig. 7A, B). These results suggest that INGAP may affect the NF-κB signaling through p65 phosphorylation, potentially modulating p65 transcriptional activity or stability. Interestingly, inhibition of P-p65 (Ser536) was further increased when rINGAP was used together with IKKVII inhibitor.
Fig. 1 (See legend on next page.)
(Supplementary Fig. 7C, D), suggesting that besides IKK, INGAP may target other kinases implicated in p65 phosphorylation at Ser536.

**Effects of rINGAP on NF-κB signaling is observed when cytokines are used together but not separately**

To better understand the impact of rINGAP on NF-κB signaling, we repeated the experiment with each cytokine separately. As expected, NF-κB pathway was induced by IL-1β but not by IFNγ, which, however, potentiated the effects of IL-1β on phosphorylation of IKK and IκBα (Fig. 5a–c), and on iNOS expression (Fig. 5e). p65 phosphorylation was not enhanced by IFNγ (Fig. 5d), indicating that it was under control of IL-1β only. Interestingly, all inhibitory effects of rINGAP were only observed for the cytokine cocktail but not IL-1β alone, even for p65. In the case of IKK, IκBα, and iNOS, the decreases were roughly equal to reversing the potentiation by IFNγ (Fig. 5a–c, e). This suggests that INGAP targeted the IFNγ signaling rather than IL-1β.

**INGAP is more effective against the cytokine cocktail than individual cytokines in inhibiting STAT3, p38, and JNK**

JAK2/STAT1 signaling was activated by IFNγ, resulting in phosphorylation of JAK2 (Tyr1007/1008), and STAT1 (Tyr701) at 1 h and 6 h, whereas IL-1β had no effect. In contrast, STAT3 phosphorylation (Tyr705), although induced mostly by IFNγ at 1 h, was driven mostly by IL-1β at 6 h (Fig. 6a). Used in combination, cytokines increased P-STAT3 up to 12 h of treatment (Supplementary Fig. 5B). rINGAP had no effect on STAT1 phosphorylation (Fig. 6a, c) but slightly decreased P-JAK2 induced by IFNγ or both cytokines at 6 h (Fig. 6a, b). It also inhibited P-STAT3 at 1 h and 6 h (all combinations, Fig. 6a, d), but the differences were statistically significant only for both cytokines at 6 h, corroborating that rINGAP was more potent against the cytokine cocktail.

Phosphorylation of JNK (Thr183/Tyr185) and p38 (Thr180/Tyr182), most prominent at 30 min (Supplementary Fig. 5B), was induced by IL-1β but not by IFNγ, which, however, potentiated the IL-1β effects (Fig. 7). rINGAP pre-treatment inhibited both kinases and, in keeping with earlier results, this was observed when IL-1β was used with IFNγ but not alone and was roughly equal to eliminating the effect of IFNγ.

**rINGAP downregulates expression of IFNγ-responsive genes induced by cytokine cocktail**

Since rINGAP did not inhibit p65 nuclear translocation or JAK2/STAT1 phosphorylation, we examined next whether it affected the expression of the downstream target genes. We chose several known IL-1β/NF-κB-stimulated and IFNγ-stimulated genes involved in β-cell apoptosis for analysis by qRT-PCR. Based on cytokine responsiveness, selected genes were categorized into: (1) IL-1β-induced (e.g., NF-κB2, Sod2, Cxcl1); (2) IL-1β-induced and IFNγ-potentiated (Nos2); (3) pre-dominantly IFNγ-induced (Irf1, Socs1, Socs3); and (4) non-canonical NF-κB-associated genes (Fbw7, Cebpd, Nik) (Supplementary Table 1, Fig. 8). Although the time of induction differed among these genes, at 3 h post cytokines all genes were elevated, favoring this time point for rINGAP experiments. In keeping with the lack of effect on NF-κB, rINGAP had no effect on the IL-1β-induced genes but downregulated the IFNγ-induced genes (Fig. 8a, b). However, once again, the effect was observed only with both cytokines and not IFNγ alone. Among the genes involved in regulation of noncanonical NF-κB pathway, Nik (NF-κB inducing kinase) appeared also downregulated by rINGAP, albeit the change was not statistically significant. Likewise, only a trend and no significant change was shown for Fbw7 and Cebpd (Fig. 8c).

**Discussion**

This is the first study to demonstrate the anti-apoptotic effects of recombinant INGAP and INGAP-peptide in the cytokine-treated β cells. Although pro-survival effects of
INGAP have been reported\textsuperscript{29,33}, the impact of pro-inflammatory conditions was not evaluated. In this work, we used a common model of cytokine-induced death that employs IL-1\textbeta and IFN\gamma, two cytokines most implicated in the development of diabetes\textsuperscript{5,6}. In contrast to other studies, we also used each cytokine separately to better understand the underlying signaling events. Our main findings are: (1) both rINGAP and Ingap-p reduced cytokine-induced apoptosis, which correlated with inhibition of cleaved Caspase-3 and of the iNOS-NO axis; (2) rINGAP inhibited phosphorylation of p38, JNK, STAT3, and the constituents of NF-\kappaB pathway, whereas nuclear translocation of NF-\kappaB and the downstream gene expression was not inhibited; (3) rINGAP was more
effective against the cytokine cocktail than each cytokine separately and appeared to reverse the potentiating effects of IFN\(\gamma\); (4) expression of IFN\(\gamma\)-stimulated genes was downregulated by rINGAP when cytokines were used in combination but not IFN\(\gamma\) alone; (5) taken together, our data suggest that rINGAP affects the crosstalk between IL-1\(\beta\) and IFN\(\gamma\) signaling.

In keeping with our previous research\textsuperscript{16,17}, we compared the effects of rINGAP and Ingap-p. Ingap-p, shown to reproduce the effects of the INGAP protein\textsuperscript{11}, has been used in multiple studies worldwide\textsuperscript{22–29} including clinical trials\textsuperscript{19}. The interest in Ingap-p is obvious because it is synthetic and well-tolerated by patients\textsuperscript{13,19}. However, as we have previously shown, rINGAP is more stable and over 100× more potent on a molar basis than Ingap-p, and it interacts differently with the cell surface, which may potentially lead to different outcomes\textsuperscript{11,16,17}. Here again, we demonstrate a stronger potency for rINGAP versus Ingap-p in inhibiting apoptosis, improving viability (72 h vs 24 h), and reducing NO production (48 h vs 24 h). Importantly, rINGAP demonstrated a “rescue” effect when administered 2 h post cytokines, whereas Ingap-p was effective only in pre- and co-treatment modes. Whereas a greater stability of rINGAP could account for a
stronger improvement in viability, the “rescue” effect clearly points to some differences in the mechanism of action. These differences would be interesting to explore to potentially design a better peptide for future clinical use.

Among signaling pathways involved in cytokine-induced β-cell death, NF-κB plays a major role, exerted mainly through activation of iNOS expression and NO production. Although cytokines may act in a NO-independent fashion, the critical role of NO in IL-1β/NF-κB-induced β-cell dysfunction and apoptosis has been well established. Inhibition of NF-κB signaling leads to cytoplasmic retention of p65 that halts its transcriptional activity. As we showed, although rINGAP and Ingap-p decreased IL-1β + IFNγ-induced phosphorylation of IKK, IkBa, and p65, p65 nuclear translocation was not inhibited and even slightly enhanced. This result was unexpected, as it somewhat contradicted the inhibitory effects of INGAP on iNOS expression/NO production and on the aforementioned phosphorylation events. We then investigated by qRT-PCR the expression of several NF-κB-regulated chemokine genes to test whether rINGAP inhibited the p65 transcriptional activity. Expression of NF-κB2, Sod2, Cxcl1 shown in Fig. 8a,
plus a few others, such as Ccl2, Lcn2, Ccl5, Ccl19 (data not shown) upregulated by IL-1β ± IFNγ, but not by IFNγ, was not reduced by rINGAP. We, therefore, concluded that rINGAP did not inhibit NF-κB signaling. The significance of the INGAP effect on p65 phosphorylation is less clear, as the role of phosphorylation in the IκBα-regulated p65 translocation and transcriptional activity is poorly understood. Aside from the IKK complex (mostly IKKβ)\(^{52,62}\), several kinases such as RSK1, MSK1, TAK1 have been shown to phosphorylate p65 on Ser536 \(^{52}\). There is evidence that phosphorylation may promote p65 disassociation from IκBα and p50, which carries a dominant nuclear export sequence \(^{63,64}\), causing a delayed nuclear translocation \(^{65}\) or an increase in p65 turnover \(^{66}\). It is possible, therefore, that inhibition of p65 phosphorylation by INGAP contributed to accumulation and/or a delayed degradation of nuclear p65 observed in this study. We show that p65 phosphorylation is induced by IL-1β and is not affected by IFNγ. It is not clear, however, why rINGAP inhibited p65 phosphorylation only when IL-1β was used together with IFNγ but not alone. It is possible that rINGAP and IFNγ synergistically inhibit one of the kinases that phosphorylate p65, whereas such a synergy is absent between INGAP and IL-1β but to verify this possibility a more-detailed investigation into the signaling pathways of IFNγ and rINGAP is needed. IFNγ is often used with IL-1β to model the diabetic milieu, although its role in β-cell apoptosis and the signaling pathways leading to it are less understood. We show that IFNγ had no effect on the NF-κB-iNOS-NO axis but potentiated the action of IL-1β on the phosphorylation of IKK, IκBα, and significantly increased iNos expression. As rINGAP eliminated the IFNγ-potentiating effects, we reasoned that it targeted IFNγ signaling and

![Fig. 5 rINGAP pre-treatment inhibits NF-κB signaling when IL-1β and IFNγ used together but not individually.](image)
Fig. 6 (See legend on next page.)
screened for known IFN-γ-responsive genes\textsuperscript{54}. Of note, out of several genes tried, only three—Irf1, Socs1, and Socs3, were induced by IFN-γ more than by IL-1β. We show that rINGAP indeed reduced the expression of these genes but, once again, for the cocktail of both cytokines and not IFN-γ alone. rINGAP did not inhibit STAT1 phosphorylation, which is required for IFN-γ signaling\textsuperscript{67}. This suggests that INGAP targets neither IFN-γ nor IL-1β specifically but modulates the crosstalk between the two, the precise mechanisms of which are yet to be elucidated.

Cytokine signaling involves multiple pathways. IL-1β has been shown to activate several signaling pathways including NF-κB, JAK/STAT, PI3K, and MAPK\textsuperscript{30,41,48}. Likewise, IFN-γ-induced signaling, previously thought to be limited to JAK/STAT1 pathway, has been expanded to include STAT3, STAT5, Src family of non-receptor tyrosine kinases, PI3K, NF-κB, MAP kinases that are recruited by IFNγR or JAK\textsuperscript{42,68}. These pathways constitute a complex network that may account for multiple effects elicited by IFN-γ alone, and in combination with IL-1β\textsuperscript{45,46,67}. This complexity makes it difficult for us to pinpoint the possible target of INGAP, as we addressed only the most common pathways, such as NF-κB, JAK/STAT, and MAPK. However, this is the first step that builds the base for further investigation.

In addition to the complexity of cytokine crosstalk, INGAP signaling is not well understood either. No specific receptor has been identified and the existing studies
report a wide variety of INGAP-activated pathways, such as PI3K/Akt, cholinergic pathway, NF-κB, or cAMP-PKA. We have previously shown that rINGAP and Ingap-p stimulate proliferation in RINm5F cells by activating Ras-Raf-Erk1/2 pathway, which may also involve Src. However, we did not observe activation of NF-κB, PKA, p38 MAPK, or PKC in RINm5F cells by either rINGAP or Ingap-p, which is perhaps cell type specific. The search for possible mechanisms by which INGAP exerts its anti-cytokine effects might be perhaps narrowed to the Ras-Raf-Erk1/2 and PI3K/Akt pathways, which should be investigated in more detail.

In summary, INGAP has been known for its regenerative properties and the ability to reverse diabetes in animal models. Our work shows that INGAP also protects β cells from cytokine-induced apoptosis, thus providing new insights into the anti-apoptotic potential of INGAP. The significance of these findings is determined by the need to develop β-cell survival therapies for the protection of the existing or transplanted β cells in the pro-inflammatory diabetic milieu. Although this study did not propose a definite mechanism of anti-apoptotic action of INGAP, it built the foundation for further research that will also include human islets and other cytokines, e.g., TNFα, to better approximate the diabetic milieu and to better evaluate the therapeutic potential of INGAP.

Acknowledgements
We thank Dr. Reid Aikin for help with establishing the model of cytokine-induced β-cell death, Jessica Cuerquis for technical assistance, and Dr. Beatrice Assouline-Thomas for producing rINGAP and for critical reading of the manuscript.

Funding
This study was funded by the Jewish General Hospital Foundation (Montreal, QC, Canada) and by the Liana’s Dream Foundation (to LR).

Ethics statement
Our study did not use animal or human samples or data, therefore it did not require ethical approval.
Conflict of interest
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00441-z.

Received: 8 January 2021 Revised: 6 February 2021 Accepted: 14 February 2021
Published online: 17 March 2021

References
1. Atkinson M. A. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007561 (2012).
2. Rhodes, C. J. Type 2 diabetes—a matter of β-cell life and death? Science 307, 380–384 (2005).
3. Imai, Y., Dobrian, A. D., Morris, M. A. & Nadler, J. L. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol. Metab. 24, 351–360 (2013).
4. Donath, M. Y., Starling, J., Mawder, K. & Mandrup-Poulsen, T. Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J. Endocrinol. Invest. 26, 455–470 (2003).
5. de Luca, C. & Olefsky, J. M. Inflammation and insulin resistance. FEBS Lett. 582, 97–105 (2008).
6. Ezrin, D. L., Colli, M. L. & Orti, F. The role of inflammation in insulin and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5, 219–226 (2009).
7. Weaver, J. R. et al. Integration of pro-inflammatory cytokines, lipooxygenase and NOX1 in pancreatic islet beta cell dysfunction. Mol. Cell. Endocrinol. 358, 88–95 (2012).
8. Rosenberg, L., Vink, A. I., Pittergton, G. L., Rafae1off, R. & Duguid, W. P. Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor(s). Diabetologia 39, 256–262 (1996).
9. Rosenberg, L., Brown, R. A. & Duguid, W. P. A new approach to the induction of duct epithelial hyperplasia and neoductoblastosis by cellophane wrapping of the hamster pancreas. J. Surg. Res. 35, 63–72 (1983).
10. Pittergton, G. L., Vink, A. I. & Rosenberg, L. The partial isolation and characterization of iotropin, a novel islet-specific growth factor. Adv. Exp. Med Biol. 321, 123–130 (1992), discussion 131-122.
11. Rafae1off, R. et al. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J. Clin. Invest. 99, 2100–2109 (1997).
12. Rafae1off, R., Qin, X. F., Barlov, S. W., Rosenberg, L. & Vink, A. I. Identification of differentially expressed genes induced in pancreatic islet neogenesis. FEBS Lett. 378, 219–223 (1996).
13. Rosenberg, L. et al. A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57Bl/6J mice. Ann. Surg. 240, 875–884 (2004).
14. Pittergton, G. L. et al. Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs. Pancreas 34, 103–111 (2007).
15. Jamal, A. M. et al. Morphogenetic plasticity of adult human pancreatic islets of Langerhans. Cell. Differ. 12, 702–712 (2005).
16. Assouline-Thomas, B. et al. Production and characterization of the recombinant islet Neogenesis Associated Protein (INGAP). Protein Expr. Purif. 69, 1–8 (2010).
17. Petrovapovskia, M. et al. Mechanisms of action of islet neogenesis-associated protein: comparison of the full-length recombinant protein and a bioactive peptide. Am. J. Physiol. Endocrinol. Metab. 303, E917–E927 (2012).
18. Assouline-Thomas, B. et al. Islet Neogenesis Associated Protein (INGAP) induces the differentiation of an adult human pancreatic ductal cell line into insulin-expressing cells through stepwise activation of key transcription factors for embryonic beta cell development. Differ. Res. Biol. diversity 90, 77–90 (2015).
19. Dungan, K. M., Buse, J. B. & Ratner, R. E. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab. Res. Rev. 25, 558–565 (2009).
20. Li, J. et al. Islet neogenesis-associated protein-pentadecapeptide enhances the differentiation of islet-like clusters from human pancreatic duct cells. Peptides 30, 2242–2249 (2009).
21. Kapur, R. et al. Short-term effects of INGAP and Reg family peptides on the appearance of small beta-cells clusters in non-diabetic mice. Islets 4, 40–48 (2012).
22. Borell, M. I. et al. INGAP-related pentadecapeptide its modulatory effect upon insulin secretion. Regul. Pept. 131, 97–102 (2005).
23. Flores, L. E. et al. Islet neogenesis-associated protein (INGAP): the role of its endogenous production as a positive modulator of insulin secretion. Regul. Pept. 192–193, 30–34 (2014).
24. Madrid, V. et al. Islet neogenesis-associated protein pentadecapeptide (INGAP-PP) mechanisms involved in its effect upon beta-cell mass and function. Regul. Pept. 157, 25–31 (2009).
25. Barbosa, H. et al. Islet neogenesis-associated protein (INGAP) modulates gene expression in cultured neonatal rat islets. Regul. Pept. 136, 78–84 (2006).
26. Barbosa, H. C. et al. Islet neogenesis-associated protein signaling in neonatal pancreatic rat islets: involvement of the cholinergic pathway. J. Endocrinol. Invest. 29, 360–366 (2006).
27. Maiztegui, B., Roman, C. L., Barbosa-Sampaio, H. C., Boschiero, A. C. & Gagliardino, J. J. Role of islet glucokinase, glucose metabolism, and insulin pathway in the enhancing effect of islet neogenesis-associated protein on glucose-induced insulin secretion. Pancreas 44, 959–966 (2015).
28. Silva, K. E. et al. INGAP-PP up-regulates the expression of genes and proteins related to K+ – ATP channels and ameliorates Cu2+ handling in cultured adult rat islets. Regul. Pept. 148, 39–45 (2008).
29. Zha, M. et al. Effects of islet neogenesis-associated protein pentadecapeptide on cell mass and insulin secretion of pancreatic beta-cells. J. Endocrinol. Invest. 35, 634–639 (2012).
30. Román, C. I., Maiztegui, B., Del Zotto, H., Gagliardino, J. J. & Flores, L. E. INGAP-PP effects on β-cell mass and function are related to its positive effect on islet angiogenesis and VEGFA production. Mol. Cell. Endocrinol. 470, 269–280 (2018).
31. Madrid, V. et al. Islet neogenesis-associated protein (INGAP)-positive cell mass, beta-cell mass, and insulin secretion: their relationship during the fetal and neonatal periods. Pancreas 42, 422–428 (2013).
32. Madrid, V. et al. Islet neogenesis-associated protein pentadecapeptide (INGAP-PP) mechanisms involved in its effect upon β-cell mass and function. Regul. Pept. 157, 25–31 (2009).
33. Chen, H. et al. Islet neogenesis-associated protein-related pentadecapeptide improves the function of allograft after islets transplantation. J. Pediatr. Endocrinol. Metab. 27, 1167–1173 (2014).
34. Taylor-Fishwick, D. A. et al. Islet neogenesis-associated protein transgenic mice are resistant to hyperglycemia induced by streptozotocin. J. Endocrinol. 190, 729–737 (2006).
35. Chang, T. J. et al. Targeted expression of islet neogenesis associated protein to beta cells enhances glucose tolerance and confers resistance to streptozotocin-induced hyperglycemia. Mol. Cell. Endocrinol. 335, 104–109 (2011).
36. Paraskevas, S. et al. Activation and expression of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival. FEBS Lett. 455, 203–208 (1998).
37. Rosenberg, L., Wang, R., Paraskevas, S. & Maysinger, D. Structural and functional changes resulting from islet isolation lead to islet cell death. Surgery 126, 393–398 (1999).
38. Kanak, M. A. et al. Inflammatory response in islet transplantation. Int. J. Endocrinol. 2014, 431035 (2014).
39. Negi, S. et al. Analysis of beta-cell gene expression reveals inflammatory signaling and evidence of dedifferentiation following human islet isolation and culture. PloS ONE 7, e30415 (2012).
40. Meyerovitch, K. et al. The non-canonical NF-κappaB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro. Diabetologia 59, 512–521 (2016).
41. Burke, S. J. et al. L1-beta reciprocally regulates chemokine and insulin secretion in pancreatic beta-cells via NF-κappaB. Am. J. Physiol. Endocrinol. Metab. 309, E715–E726 (2015).
42. Thomas, H. E. et al. Interferon signalling in pancreatic beta cells. Front. Biosci. 14, 644–656 (2009).
43. Hu, X. & Isailkhv, L. B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31, 539–550 (2009).
44. Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279, 41679–41685 (2004).
45. Heitmeier, M. R., Scarr, A. L. & Corbett, J. A. Interferon-γ increases the sensitivity of islets of langerhans for inducible nitric-oxide synthase expression induced by interferon 1. J. Biol. Chem. 272, 13697–13704 (1997).
46. Thomas, H. E., Danwirche, R., Corbett, J. A. & Kay, T. W. H. Interleukin-1 plus γ-interferon-induced pancreatic β-cell dysfunction is mediated by β-cell nitric oxide production. Diabetes 51, 311–316 (2002).
47. Thomas, H. E., Dutton, R., Bartlett, P. F. & Kay, T. W. Interferon regulatory factor 1 is induced by interferon-gamma equally in neurons and glial cells. J. Neuroimmunol. 78, 132–137 (1997).
48. Saldren, J., Lee, J. C. & Welsh, N. Role of p38 mitogen-activated protein kinase (g38 MAPK) in cytokine-induced rat islet cell apoptosis. Biochem. Pharmacol. 61, 1561–1569 (2001).
49. Ammendrup, A. et al. The c-Jun aminoterminal kinase pathway is preferentially activated by interferon-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 49, 1466–1476 (2000).
50. Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 21, 103–115 (2011).
51. O’Dea, E. & Hoffmann, A. NF-kappaB signaling. Wiley Interdiscip. Rev. Syst. Biol. Med. 1, 107–115 (2009).
52. Christian, F., Smith, E. L. & Carmody, R. J. The regulation of NF-kappaB subunits by phosphorylation. Cell 5, 12 (2016).
53. Buss, H. et al. Constitutive and interferon-1-inducible phosphorylation of p65 NF-kappaB at serine 536 is mediated by multiple protein kinases including I kappaB kinase (IκBα), IκBβ, IκK(epsilon), TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor I31-mediated interferon-1 transcription. J. Biol. Chem. 279, 55653–55664 (2004).
54. Panarina, M. et al. Interferon and interferon-inducible gene activation in patients with type 1 diabetes. Scand. J. Immuno. 80, 283–292 (2014).
55. Melloul, D. Role of NF-kappaB in beta-cell death. Biochem. Soc. Trans. 36, 334–339 (2008).
56. Ezirko, D. L. et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invesg. 93, 1968–1974 (1994).
57. Anikartono, M., Dypbukt, J. M., Briune, B. & Nicotera, P. Interleukin-1β-induced nitric oxide production activates apoptosis in pancreatic RINm5F cells. Exp. Cell Res. 213, 172–177 (1994).
58. Muhammed, S. J., Lundquist, I. & Saleh, A. Pancreatic β-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes. Diabetes Obes. Metab. 14, 1010–1019 (2012).
59. Alderton, W. K., Cooper, C. E. & Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357, 593–615 (2001).
60. Arafat, H. A. et al. Osteopontin protects the islets and beta-cells from interleukin-1β-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 148, 575–584 (2007).
61. Ivanovsko, M., Brasier, A. R. & Kimmell, M. The dependence of expression of NF-κB-dependent genes: statistics and evolutionary conservation of control sequences in the promoter and in the 3’UTR. BMC Genomics 13, 182–182 (2012).
62. Sakurai, H., Chiba, H., Miyoshi, H., Sugita, T. & Toriumi, W. IkB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274, 30353–30356 (1999).
63. Bohuslav, W. C. et al. p38 induces NF-κB activation by an IkB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279, 26115–26125 (2004).
64. Sasaki, C. Y., Barberi, T. J., Ghosh, P. & Longo, D. L. Phosphorylation of RelA/p65 on serine 536 defines an IkappaB(alpha)-independent NF-κB pathway. J. Biol. Chem. 280, 34538–34547 (2005).
65. Mattioli, I. et al. Transient and selective NF-kappaB B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappaB kinase beta and controls the kinetics of p65 nuclear import. J. Immunol. 172, 6336–6344 (2004).
66. Lawrence, T., Beiben, M., Liu, G. Y., Nizat, V. & Karin, M. IkBalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434, 1138–1143 (2005).
67. Gysemans, C., Callewaert, H., Overbergh, L. & Mathieu, C. Cytokine signalling in the β-cell: a dual role for IFNγ. Biochem. Soc. Trans. 36, 328–333 (2008).
68. Gough, D. J., Levy, D. E., Johnstone, R. W. & Clarke, C. J. IFNγ signaling—does it mean JAK-STAT? Cytokine Growth Factor Rev. 19, 383–394 (2008).
69. Paula, F. M. et al. Requirement of NF-kappaB signalling pathway for modulation of the cholinergic muscarinic M3 receptor expression by INGAP-PP in insulin-producing cells. Eur. J. Pharmacol. 642, 37–46 (2010).
70. Tani, J., Diamond, J. & Maysinger, D. Dual-action peptides: a new strategy in the treatment of diabetes-associated neuropathy. Drug Discov. Today 11, 254–260 (2006).
71. Fleming, A. R. L. The prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein (INGAP). J. Diabetes Sci. Technol. 1, 231–244 (2007).